SCHEMBL6076752

SCHEMBL6076752

O=C1NC(c2ccccc2)C(=O)N2C(=O)SCC12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
AR P10275 1/20 0.37
OTUD7B Q6GQQ9 1/20 0.36
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 4/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK10 P53779 1/20 0.34
EP300 Q09472 1/20 0.34
CREBBP Q92793 1/20 0.34
CA2 P00918 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077778 0.71 KMT2A (0.37) LMNAADORA3MAPTALDH1A1KMT2A
SCHEMBL15669931 0.69 MAPT (0.48) LMNAADORA3MAPTALDH1A1KMT2A
SCHEMBL1894049 0.69 MAPT (0.48) LMNAADORA3MAPTALDH1A1KMT2A
SCHEMBL1895535 0.69 MAPT (0.48) LMNAADORA3MAPTALDH1A1KMT2A
SCHEMBL6078148 0.68 NPSR1 (0.43) LMNAKMT2AKDM4EGAAMEN1
SCHEMBL11400689 0.66 KMT2A (0.40) LMNACYP3A4MAPTALDH1A1KMT2A
SCHEMBL6078380 0.66 TACR1 (0.47) CYP3A4CYP2C9CYP2C19MAPTKDM4E
Methane SCHEMBL11336749 0.65 MAPT (0.48) LMNAADORA3MAPTALDH1A1KMT2A
SCHEMBL6077284 0.65 KMT2A (0.40) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL9525052 0.65 DDB1 (0.44) MAPTALDH1A1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022317-B2 Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL (FR) 2006-04-04 US claimed
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL S.A. (FR) 2005-06-16 US claimed
EP-1471067-A1 Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent L'OREAL (FR) 2004-10-27 EP claimed
US-7022317-B2 Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL (FR) 2006-04-04 US disclosed
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents L'OREAL S.A. (FR) 2005-06-16 US disclosed
EP-1471067-A1 Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent L'OREAL (FR) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129635-A1 Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents CUTA, OGDH, TYR LMNA 3284/4885ADORA3 2460/4885AR 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.